Assessing the efficacy of emotion-focused therapy in the treatment of depression, anxiety and related disorders

Not Applicable

• Conditions: Depression and anxiety and related disorders (such as obsessive-compulsive disorders and trauma/stressor related disorders).; Mental and Behavioural Disorders

• Registration Number: ISRCTN11430110
• Lead Sponsor: Trinity College Dublin

Brief Summary

2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/32296754/https://pubmed.ncbi.nlm.nih.gov/32296754/ (added 11/07/2022)

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-07
• Last Update Posted: 24 June 2024
• Study Completion: 2025-06-30

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Meet the criteria for depression, an anxiety disorder and/or related disorder (obsessive-compulsive disorders and trauma/stressor related disorders) as a principal diagnosis.
2. If taking psychotropic medication then must be stabilised on that medication for 6 weeks prior to commencing therapy.
2.1. Shows, with their physician’s approval, a willingness to maintain this stability in medication use during the period of therapy

Exclusion Criteria

1. Concurrent psychological treatment
2. Suicide risk
3. Risk of harm to others
4. Substance abuse
5. Psychosis
6. Organic brain syndrome

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To be measured at pre-therapy, post therapy (16 weeks; but also post last session in cases where the last session falls outside the range of 16 ± 2 weeks) and at 6-month follow up:<br>1. Anxiety severity will be measured using the Anxiety Severity and Impairment Scale (OASIS; Norman, Cissell, Means-Christensen, Stein, 2006).<br>2. Depression severity will be measured using the Overall Depression Severity and Impairment Scale (ODSIS; Bentley, Gallagher, Carl, & Barlow, 2014).<br>3. Psychological distress will be measured using the CORE-OM will also be used by all participants pre-, post, and at 6-month follow-up.